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T H E NEED FOR STANDARDIZATION 
OF METHODOLOGY AND COMPONENTS 
IN COMMERCIAL RADIOIMMUNOASSAY KITS* 
W.G. WOOD, I . MARSCHNER, P.C. SCRIBA 
Medizinische Klinik Innenstadt 
der Universität München, 
Munich, Federal Republic of Germany 
Abstract 
T H E NEED FOR S T A N D A R D I Z A T I O N OF M E T H O D O L O G Y A N D COMPONENTS I N 
C O M M E R C I A L R A D I O I M M U N O A S S A Y KITS . 
The problems arising from the increasing use of commercial kits in radioimmunoassay 
( R I A ) and related fields are discussed. These problems differ according to the substance under 
test. The quali ty o f individual reagents is often good, but the methodology is often not optimal 
and may contain short-cuts which, although commercially attractive, can lead to erroneous 
values and poor sensitivity and precision. Minor modifications in the methodology often 
lead to big improvements in sensitivity and precision. This has been demonstrated in three 
digoxin kits employing antibody-coated tube techniques and in four kits for thyro t rop in (TSH) 
using different techniques. It has also been noted that w i t h many quali ty-control sera 
imported from the USA no values are ascribed to European kits for the components listed, 
thus reducing these sera to the function o f precision control . The study underlines the need 
to standardize k i t components and assay methods to enable the results obtained by different 
laboratories wi th different kits to be compared. 
The decentralized nature of health care in the Federal Republic of 
Germany (FRG) has contributed to the rapid increase in the use of commercial 
kits in RIA and associated techniques. The problems arising from the extended 
use of kits are many and they are not only concerned with methodology. The 
differing results obtained for certain substances with kits from different manu-
facturers may lead to a false diagnosis when only the absolute values are compared 
without reference to the given normal range. This problem arises particularly 
with the Proteohormones. 
Table I is an excerpt from the values ascribed to digoxin, TSH and insulin 
in different kits of commercial quality-control sera. For each component the 
control sera are at three concentrations with the aim of controlling low, middle 
and high ranges of the standard curve. For the drug digoxin, which is not 
normally present in serum, it can be seen from Table I that the measured values 
* Supported by the Bundesministerium für Forschung und Technologie. 
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TABLE I . VALUES ASCRIBED TO DIFFERENT KITS FOR DIGOXIN, TSH AND INSULIN IN COMMERCIAL 
QUALITY-CONTROL SERA 
(Taken from manufacturers' data) 
Test 
Vit 
Level 1 Level 2 Level 3 
(units) mean ± 2 SD mean ± 2 SD mean ± 2 SD 
Digoxin (ng/ml) 
Abbot t 0.6 ± 0.16 1.7 ± 0 . 2 8 3.0 ± 0.54 
Amersham/Searle 0.7 ± 0.04 1.8 ± 0.12 3.0 ± 0 . 2 4 
Beckman 0.9 ± 0.12 1.9 ± 0.16 3.1 ± 0.38 
Burroughs Wellcome 0.8 ± 0 . 1 0 1.8 ± 0.12 3.1 ± 0 . 3 2 
Clinical Assays 0.8 ± 0 . 1 6 2.0 ± 0.24 3.0 ± 0 . 2 2 
Corning 0.8 ± 0.12 1.9 ± 0 . 2 6 2.9 ± 0.40 
Curtis 1.0 ± 0 . 2 6 2.0 ± 0 . 3 6 3.2 ± 0.28 
Kallestad 3 Η 0.8 ± 0.24 1.8 ± 0 . 5 0 2.8 ± 0.54 
Kallestad 1 2 5 1 0.8 ± 0.06 1.8 ± 0 . 2 2 3.0 ± 0 . 2 4 
Micromedic 0.8 ± 0.16 1.9 ± 0 . 2 4 3.1 ± 0.48 
Dade 0.8 ± 0.08 2.0 ± 0 . 1 6 3.2 ± 0.20 
NEN 1 2 5 I 0.8 ± 0.18 1.8 ± 0.12 3.0 ± 0.20 
NEN 1 2 5 I Solid Phase 0.7 ± 0.08 1.7 ± 0.12 3.0 ± 0 . 3 0 
Radioassay Systems 0.6 ± 0.14 1.6 ± 0.20 3.0 ± 0.46 
Schwarz-Mann 0.8 ± 0.10 2.0 ± 0.28 3.4 ± 0.60 
Squibb 0.8 ± 0.20 1.6 ± 0.20 2.5 ± 0.40 
T A B L E I (cont.) 
(units) 
TSH ( μ ϋ / m l ) 
Abbot t 
Diagnostic Products 
Nichols Inst i tute 
Radioassay Systems 
Beckman 
Insulin (μυ/ml) 
Amersham/Searle 
Corning 
Curtis 
Schwarz-Mann 
Pharmacia 
Level 1 Level 2 Level 3 
mean ± 2 SD mean ± 2 SD mean ± 2 SD 
5.3 ± 1.28 15.2 ± 3.10 47.3 ± 16.20 
8.7 ± 0 . 7 6 19.6 ± 1.20 38.6 ± 2 . 8 2 
4.6 ± 0 . 7 5 15.7 ± 1.64 32.3 ± 2.90 
4.4 ± 1.86 13.6 ± 1.62 29.9 ± 1.96 
6.1 ± 0 . 7 2 15.5 ± 3 . 8 4 38.1 ± 13.24 
15 ± 3.1 39 ± 3.5 101 ± 11.1 
17 ± 4 . 4 38 ± 8.0 112 ± 12.3 
6 ± 0 . 6 32 ± 8 . 0 87 ± 11.7 
13 ± 2.2 34 + 4.1 105 ± 21.7 
24 ± 7 . 5 50 ± 8.5 115 ± 27.1 
> 
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TABLE I I . VALUES ASCRIBED TO DIFFERENT KITS FOR Τ 3 „ CORTISOL 
AND T 4 IN COMMERCIAL QUALITY-CONTROL SERA 
(Taken from manufacturers' data) 
Test 
(units) 
K i t 
Level 1 
mean ± 2 SD 
Level 2 
mean ± 2 SD 
Level 3 
mean ± 2 SD 
T 3 R I A (ng/dl) 
Beckmann 61.1 ± 11.54 163.6 ± 26.56 390.0 ± 80.46 
Abbot t 107.0 ± 3 2 . 0 0 250.0 ± 7 2 . 0 0 530.0 ± 190.0 
Ames 85.4 ± 13.72 196.0 ± 2 1 . 4 8 428.3 ± 59.74 
Amersham/Searle 65.0 ± 8 . 0 0 170.0 ± 2 2 . 0 444.0 ± 46.00 
Corning 45.5 ± 7.84 147.6 ± 2 8 . 5 2 328.9 ± 60.94 
Curtis 72.4 ± 3 0 . 6 2 195.3 ± 3 1 . 7 6 384.4 ± 35.72 
Diagnostic Products 78.1 ± 8 . 4 4 165.5 ± 11.60 356.6 ± 4 2 . 1 6 
Maloy Laboratories 101.6 ± 10.16 245.6 ± 4 1 . 3 0 536.6 ± 53.40 
Nichols Institute 71.1 ± 10.5-8 173.8 ± 2 0 . 8 4 402.9 ± 3 4 . 0 1 
Radioassay Systems 43.9 ± 17.46 147.9 ± 20.82 349.8 ± 29.34 
Cortisol (Mg/dl) 
Amersham/Searle 6.4 ± 0.60 24.3 ± 3 . 3 8 > 4 1 
Clinical Assays 3 Η 4.6 ± 1.88 21.4 ± 5.16 57.8 ± 14.12 
Clinical Assays 1 2 5 1 5.3 ± 1.48 21.6 ± 6 . 9 6 51.7 ± 16.76 
Diagnostic Products 5.6 ± 0 . 6 2 23.4 ± 2 . 7 4 52.1 ± 4 . 8 0 
N E N 5.0 ± 0 . 8 2 21.5 ± 4 . 3 8 51.3 ± 7.32 
Micromedic Autopak 5.2 ± 0.84 18.0 ± 1.34 34.9 ± 3.22 
Micromedic 5.4 ± 1.02 20.6 ± 2.28 40.7 ± 9.04 
Radioass. Syst. 4.8 ± 1.32 17.8 ± 3.00 51.6 ± 6.89 
Schwarz-Mann 4.7 ± 1.46 17.3 ± 5.48 39.5 ± 1 1 . 0 0 
T 4 (Mg/dl) 
Dade CPB 4.2 ± 1.08 9.3 ± 1.54 16.1 ± 1.68 
Abbo t t CPB 2.9 ± 1.31 10.2 ± 1.35 20.7 ± 3.70 
Abbot t R I A 3.4 ± 0 . 6 0 8.3 ± 0 . 7 4 15.5 ± 2.32 
Abbo t t RIA-PEG 3.6 ± 0.54 8.3 ± 1.02 15.3 ± 2.32 
Ames CPB 3.6 ± 0.84 8.5 ± 1.22 16.5 ± 1.22 
Amersham/Searle CPB 4.1 ± 0.34 11.3 ± 1.04 > 19.2 
Amersham/Searle RIA 3.8 ± 0 . 8 2 9.3 ± 0 . 9 6 17.7 ± 1.56 
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TABLE II (cont.) 
T e S t Kit 
(units) 
Level 1 
mean ± 2 SD 
Level 2 
mean ± 2 SD 
Level 3 
mean ± 2 SD 
Curtis CPB 4.0 ± 1.12 8.4 ± 1.46 14.7 ± 1.48 
Curtis RIA 4.4 ± 0.64 8.7 ± 1.08 14.9 ± 2.24 
Curtis R I A L I Q U A 5.5 ± 0 . 9 2 10.4 ± 0.90 16.1 ± 1.38 
Oxford ST A T 4 2.9 ± 0.96 5.4 ± 0 . 6 2 10.0 ± 0.84 
Oxford Column 2.2 ± 0 . 3 6 5.2 ± 0.92 9.0 ± 2.30 
are relatively constant, especially at higher concentrations. Other small molecules 
such as T 3 , T 4 and Cortisol, which occur naturally in serum together with metabolites 
of similar structure and must first be separated from a binding protein before 
assay, give a different range of values, as shown in Table I I . Here, the values from 
different kits are not so constant; in some cases the highest value is more than 
twice that of the lowest one for the same component in the same serum. Another 
point that is brought out here is that the results and precision of different kits 
produced by the same manufacturer for the same component may differ markedly. 
Larger Proteohormones show even more anomalous results, as can be seen 
in Table I . These anomalies are due to the assay systems used as well as to the 
reference preparation against which the standards are calibrated. 
Many kits are delivered with methodological weaknesses which give rise 
to far from optimal performance. Often minor changes in the protocol give rise 
to major improvements in performance. Table I I I shows the results of such 
modifications in three antibody-coated tube assays for digoxin. The danger of 
such assays is the poor precision at low concentrations because of non-specific 
binding sites. Non-specific binding can be minimized by pre-incubation before 
labelled tracer is added. In fact, the procedure for the Clinical Assays kit includes 
such a pre-incubation step and good precision is achieved over the entire range 
of the standard curve. When this step is omitted, precision and sensitivity are 
poor. The Schwarz-Mann AbTRAC kit provides not only antibody-coated 
tubes but also lyophilised tracer already in the tubes. Here, the protocol states 
that first serum and then buffer should be added to each tube in turn. If, however, 
buffer is added to all the tubes followed by serum, then precision is achieved at 
lower concentrations. The Boehringer-Mannheim kit combines the tracer and 
buffer, thus obviating the need for pre-incubation. If, however, the tracer and 
buffer from the Clinical Assays kit are used with the Boehringer tubes and 
standards, and a pre-incubation step is included, the precision improves markedly 
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TABLE I I I . RESULTS FROM ORIGINAL AND MODIFIED METHODS FOR 
THREE DIGOXIN ANTIBODY-COATED TUBE KITS 
Sensitivity* 50%** Precision CV 
% B 0 ng/ml intercept No. Mean SD 
1. Clinical Assays ng/ml 
(a) 89.8 0.24 1.09 
(b) 85.6 0.41 1.76 
2. Schwarz-Mann A b T R A C 
(a) 98.0 0.05 2.23 
(c) 95.2 0.06 1.28 
3. Boehringer-Mannheim 
(a) 99.2 0.02 2.06 
(d) 96.6 0.14 1.69 
(e) 90.4 0.40 2.64 
30 1.40 0.06 4.93 
30 3.62 0.29 7.97 
19 1.30 0.21 16.0 
19 3.90 0.16 4.00 
20 0.81 0.09 10.6 
20 3.44 0.11 3.17 
22 0.78 0.06 7.27 
22 3.83 0.28 7.28 
20 0.84 0.23 28.5 
20 4.05 0.20 4.96 
20 0.93 0.06 6.92 
20 4.24 0.17 4.15 
14 0.72 0.12 16.5 
14 3.93 0.14 3.63 
* Sensitivity is defined here and in Tables I V , V and V I as the value on the standard curve, 
3 standard deviations from the zero standard. 
** A l l data here and in Tables I V , V and V I were obtained from standard curves plot ted using 
a spline function. 
(a) Assay performed according to protocol. 
(b) Without pre-incubation. 
(c) Buffer added before serum. 
(d) Boehringer Ab-coated tubes and standards, Clinical Assays buffer and label, w i th 
pre-incubation. 
(e) As for (d) but wi thout pre-incubation. 
A further Boehringer-Mannheim digoxin k i t o f a different batch has been tested and has been 
found to give the fol lowing results under the conditions in (a). Sensitivity % B 0 = 97.0 or 
0.16 ng/ml, 50% intercept = 1.80 ng/ml, CV (1) η = 19, mean = 0.91 ng/ml , SD = 0.05 ng/ml, 
CV = 5.56%; (2) η = 14, mean = 2.89 ng/ml, SD = 0.23 ng/ml, CV = 8.03%. 
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TABLE IV. DIGOXIN STANDARDS FROM FIVE KITS MEASURED IN 
THE CLINICAL ASSAYS KIT 
Kits 
Standard 
(ng/ml) Abbot t Schwarz-Mann Squibb 
Boehringer-
Mannheim Corning 
0 0.05 0.08 0 0.05 0.10 
0.5 0.70 0.58 0.44 0.50 0.45 
1.0 1.14 1.14 0.85 1.00 0.94 
1.5 - 1.60 - - -
2.0 2.14 2.04 1.74 2.04 -
2.5 - - - - 2.35 
3.0 - 2.79 2.89 3.14 -
4.0 4.80 - - - -
5.0 - • 5.14 4.70 5.29 5.00 
at low concentrations. Omission of the pre-incubation step immediately lowers 
the precision. Pre-incubation has little or no effect at higher digoxin levels. This 
is to be expected because of the excess of unlabelled digoxin present. Pre-
incubation increases the slope of the standard curve, as seen in the reduced values 
of the 50% intercept. The results in Table I I I are taken from the assay in which 
intra-assay precision was. measured. 
The reagents of the kits are often of very high quality, as shown in Table IV: 
the standards from five different digoxin kits were measured by the Clinical 
Assays kit (standard curve range 0-8 ng/ml). The question of quality is further 
highlighted by the results from the Boehringer kit in which the coated tubes 
were tested with the Clinical Assays reagents. The problems arising from 
Proteohormone assays, which usually require a longer pre-incubation period 
before labelled tracer is added to increase sensitivity, concern methodology and 
kit components to a greater extent than in the digoxin kits. The use of standards 
in hormone-free serum instead of buffer for derivation of a standard curve has 
been described elsewhere [1 ,2 ] . Such a curve is more realistic and gives better 
results, especially at lower hormone concentrations. 
Four TSH kits were tested and modified to check their performance; the 
results are given in Tables V and V I . Table V gives the incubation details, the 
assay sensitivity and the 50% intercept together with the medium in which the 
standards were dissolved. The performance of the Kabi kit could have been 
improved greatly by pre-incubation before addition of the label, as shown by the 
sensitivity and 50% intercept values. The Schwarz-Mann kit was improved by 
TABLE V. EFFECTS OF INCUBATION PROCEDURES ON SENSITIVITY AND 50% INTERCEPT 
IN FOUR TSH KITS 
K i t Pre-inc. 
(h) 
Temp. 
(°C) 
Main inc. 
(h) 
Temp. 
(°C) 
2nd Ab 
(h) 
Temp. 
(°C) 
Sensitivity 
(%B 0 ) (μυ/ml) 
50%-intercept 
(μυ/ml) 
Kit 
standards 
K'abi* 
(a , ) - - 96 4 24 4 92.9 2.89 20.9 Buffer 
( b i ) 72 4 24 4 24 4 92.8 0.66 5.18 ( A ) * * 
Schwarz-Mann 
(ai) 2 37 3 37 1.5 37 95.1 0.77 9.35 Buffer 
( b , ) 18 RT 3 RT 1.0 RT 92.0 0.59 4.61 ( A ) 
WO 
Diagnostic Ο α 
Products Ε. 
(ai) 3 37 2 37 0.25 37 92.4 2.58 26.1 Protein 
3 37 2 RT 0.75 RT 92.8 2.85 25.9 based 
( b 2 ) 18 RT 2 RT 0.75 RT 95.9 0.96 13.7 (B) 
Henning 
(a,) 2 37 2.5 37 0.17 37 86.2 3.06 14.6 In TSH-free 
( a 2 ) 18 RT 2 RT 0.50 RT 92.9 0.81 6.92 
serum ( A ) 
* ( a x ) = Original method given wi th ki t RT = Room temperature 
(by) = Modified methods Pre-incubation = Incubation wi thout labelled hormone 
* * ( A ) = Calibrated against ΜRC 68/38 Standard Main incubation = After addit ion of labelled hormone 
(B) = Calibrated against WHO 1st IRP 1974 2nd Ab = Incubation after addit ion of precipitating antiserum 
TABLE V I . PERFORMANCE OF TSH KITS WITH COMMERCIAL CONTROL SERA, PATIENT SERA AND 
MRC 68/38 IN TSH-FREE SERUM 
(Assay notation is as in Table V) 
K_iJ 
Kabi Schwarz-Mann Diagnostic Products Henning 
Quality control assay assay assay assay 
sera ai b i a! b! a! b i b 2 a! a 2 
RIACON 1 (7.48*) 7.48 6.27 8.39 10.27 4.59 4.46 4.79 5.72 6.51 
2 (41 .0 ) 32.0 30.1 42.4 45.3 23.5 23.6 25.7 26.6 20.5 
Patient sera 
801 - O m i n T R H test 2.89 2.09 3.36 3.34 4.13 4.24 3.97 3.06 2.00 
801 - 30 m i n 13.9 14.4 23.2 27.7 17.3 15.3 16.0 12.8 12.7 
8 1 5 - 0 m i n T R H test < 2.89 0.65 0.77 1.09 < 2.58 < 2.85 < 0.96 < 3.06 < 0.81 
8 1 5 - 3 0 min < 2.89 0.64 0.93 0.59 < 2.58 < 2.85 < 0.96 < 3.06 < 0.81 
T S H Standard 
M R C 68/38 
0 . 3 9 p U / m l < 2.89 0.73 1.66 1.63 3.56 3.45 2.49 < 3.06 0.84 
0.78 < 2.89 1.01 1.81 2.07 4.65 3.19 3.26 < 3.06 0.98 
1.56 2.83 1.65 3.11 2.94 5.81 3.89 3.76 3.52 1.74 
3.12 4.57 3.05 4.17 4.94 6.99 5.70 5.19 3.66 3.04 
6.25 6.91 6.43 8.85 10.1 9.05 9.19 7.97 5.44 6.08 
12.5 11.72 13.3 18.2 19.2 ' l 4 . 5 15.5 13.2 11.0 12.6 
CO 
T A B L E VI (cont.) 
K i t 
Kabi Schwarz-Mann Diagnostic Products Henning 
Quality control assay assay assay assay 
sera a! b! aj bi ai b! b 2 2L\ a 2 
25.0 23.83 28.7 29.7 29.2 26.4 29.1 24.5 24.0 22.2 % 
50.0 61.29 51.2 > 50 > 50 65.9 61.0 55.8 47.2 48.0 § 
Normal range SL 
* V e n f b y , k i t . . 5 - 8 . 0 0.4-9.2 3 .1-9.6 0.5-4.0 manufacturer 
mean ± 2 SD 
* Mean of 4 kits listed by manufacturer (Dr. Molter, Heidelberg, F R G ) . 
All values in μυ/ml. 
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overnight incubation at room termperature instead of for a shorter time at 37°C, 
as were the Diagnostic Products and Henning kits. 
The values obtained from the patient sera, control sera and MRC Standard 68/38 
dissolved in TSH-free serum differ only at lower concentrations when the sensitivity 
for each kit is improved. The introduction of "Quick-Tests" for TSH that require 
a total incubation time of only 5 or 6 hours are a commercial innovation with 
no clinical advantages. Although the incubation time is short and the protocol 
states that the results are ready the same day, the realistic assay time is somewhat 
different. In addition to the assay time, the patients must be attended to, the 
TRH tests performed and the assay tubes and kit components prepared. In 
addition, the tubes must be counted, the assay data analysed and the results 
written up. This is only possible when all the patients present themselves very 
early in the morning and there are enough staff on hand to perform all the 
required tests! With an overnight pre-incubation a hectic morning is avoided and 
the results are available within a few hours, with better sensitivity and precision. 
The different absolute values obtained from different TSH kits often make 
it difficult for laboratories to compare results, and these comparisons are necessary 
when a patient transfers from one clinical practice to another. In such cases, 
false diagnoses can arise when the results are not compared with the normal range 
given for each method. 
A final observation is that with many commercial quality-control sera 
imported from the United States of America, values for the components listed 
are ascribed to American kits but none are ascribed to European kits. This 
means, at best, that such sera, which take up the largest part of the market for 
RIA in the Federal Republic of Germany, can only be used in precision control. 
The clear need for standardization of reagents and methods in kits has been 
stressed because of the importance of achieving inter-laboratory comparisons 
similar to those already achieved by the Deutsche Gesellschaft für Klinische 
Chemie (German Society for Clinical Chemistry) for other routine clinical 
chemical parameters. 
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DISCUSSION 
D. FULD: Don't you think that making recoveries on each sample would 
be better than extracting the standards, as you suggest? 
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W.G. WOOD: This would be better in the case of big laboratories. 
D. RODBARD: I was interested in the patient sample resulting in 155 %B/B 0 . 
This increase in binding could be due to the presence of endogenous antibodies 
to TSH (thyrotropin). At the 1967 meeting of the American Thyroid Association 
and subsequently in the Journal of Clinical Endocrinology and Metabolism, 
M. Hays et a l . 1 reported that injection of bovine TSH into human subjects could 
result in antibody formation with some biological neutralizing properties. 
Therefore, 1 would like to ask whether any of your subjects had previously 
received bovine TSH. 
I would also point out that even in the case of a double-antibody radio-
immunoassay, the presence of endogenous antibodies to an antigen may result in 
either parallel displacement and a false positive or a false negative (and elevated 
%B/B 0 ) , depending on the specificity of the second antiserum used (cf. PEETERS 
et al. Endocrinology (1977) 2 ). 
W.G. WOOD: This point is at present under investigation in our laboratory 
as well as in laboratories in Sweden and the USA. Our view is the same as yours, 
and until we hear anything to the contrary, we think that the "rogue factor" is 
either an antibody to bovine or perhaps human TSH. 
As the sera were pooled from more than 100 patients according to TSH 
content, and not according to names, we have unfortunately no data as to 
whether any patient had undergone prior treatment with bovine TSH. 
Your comment on the possibility of false values with the double-antibody 
assays in this case is very important and should be borne in mind when such 
cases arise. As we have not yet fully analysed the results of the TSH quality-
control survey in which these two sera were assayed, we have not yet been able 
to assess whether the different methods or kits using double-antibody methods 
give different results, which would support your theory! 
K. PAINTER: One can see that your results on coated-tube digoxin assays 
would lead you to believe that the pre-incubation step is necessary in coated-tube 
assays. However, you are seeing an effect, rather than a cause, of the problem. 
There are coated-tube digoxin assays on the market which do not behave in this 
way. The problem lies in the chemical structure of the iodinated digoxin 
derivative and in components added to the tracer buffer. The relevant studies 
of structure-function relationship will be published shortly. They contradict 
your conclusion that the reagents are good but the methodology is not. 
1 H A Y S , M.T. , SOLOMON, D .H. , B E A L L , G.N., Suppression o f human thyroid function 
by antibodies to bovine thyro t rop in , J. Clin. Endocrinol. Metab. 27 (1967) 1540. 
2 PEETERS, S., FRIESEN, H.G., R O D B A R D , D. , Growth hormone binding factor in 
serum of pregnant mice, Endocrinology 101 (1977) 1 164. 
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W.G. WOOD: I can only reiterate that our experience with coated-tube 
assays, not only for digoxin, but for digitoxin, T 4 , Cortisol and phenytoin, shows 
the same effect of pre-incubation on precision at low dose levels. Therefore I 
must stick to the results we have obtained and the logical explanation which we 
have derived from them. I should add that the coated tubes tested came from 
several different producers. 
